Molecular Subtyping in Breast Cancer
Massimo Cristofanilli, MD, director, Breast Care Center, Jefferson University Hospitals, discusses molecular subtyping in the diagnosis and treatment of breast can
Clinical Pearls
Massimo Cristofanilli, MD, director, Breast Care Center, Jefferson University Hospitals, discusses molecular subtyping in the diagnosis and treatment of breast cancer.
- ASCO and CAP are trying to better define patients who may benefit from treatment with targeted therapies
- The current method of detecting HER2 overexpression/amplification may miss a portion of patients; molecular subtyping is a more accurate way to identify these patients
- A different molecular profiling signature should be offered to patients who are defined by current guidelines as 'borderline'
<<<
Therapy Type and Site of Metastases Factor into HR+, HER2+ mBC Treatment
December 20th 2024During a Case-Based Roundtable® event, Ian Krop, MD, and participants discussed considerations affecting first- and second-line treatment of metastatic HER2-positive breast cancer in the first article of a 2-part series.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
ctDNA Detection Tied to Tumor Burden, Recurrence in HR+ Early Breast Cancer
December 13th 2024A phase 2 trial showed ctDNA detection in HR-positive early breast cancer was linked to larger tumors, higher residual cancer burden, and increased recurrence after neoadjuvant endocrine therapy.
Read More
